arrow
R

Ronan J. Kelly

baylor university
H指数:48
被引数:1.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

NK cell-derived extracellular vesicles enhance cytotoxicity and immune cell recruitment in non-small cell lung cancer

NK细胞来源的外泌体增强非小细胞肺癌的细胞毒性和免疫细胞募集

2025-07-260
OA
Decoding resistance to immune checkpoint inhibitors in non-small cell lung cancer: a comprehensive analysis of plasma proteomics and therapeutic implications

解读非小细胞肺癌对免疫检查点抑制剂的耐药性:血浆蛋白质组学及其治疗意义的综合分析

2025-05-220
OA
Clinical outcomes and ctDNA correlates for CAPOX BETR: a phase II trial of capecitabine, oxaliplatin, bevacizumab, trastuzumab in previously untreated advanced HER2+gastroesophageal adenocarcinoma
2024-08-091
OAAI
Comprehensive genomic and transcriptomic analyses capture the effects of epigenetic therapy priming on immune checkpoint blockade response in non-small cell lung cancer
2024-03-220
PRE
Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses

新辅助nivolumab或nivolumab联合LAG-3抑制剂relatlimab治疗可切除食管/胃食管交界处癌: Ib期试验和ctDNA分析

2024-03-1913
OAAI
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer
2023-06-0714
OAAI
Adjuvant nivolumab vs placebo in resected esophageal or gastroesophageal junction cancer following neoadjuvant chemoradiotherapy: First report of comprehensive biomarker analyses from CheckMate 577
2023-06-011
OA
Long term results and ctDNA correlatives for CAPOX BETR: A multi-center phase II trial of capecitabine, oxaliplatin, bevacizumab and trastuzumab for previously untreated HER2 positive metastatic gastroesophageal adenocarcinoma
2023-04-140
PRE
A machine learning approach to determine the cellular origin of variants in liquid biopsies
2023-04-040
PRE
Circulating cell-free tumor DNA dynamics capture minimal residual disease with neoadjuvant immune checkpoint blockade plus chemoradiotherapy for patients with operable esophageal/gastroesophageal junction cancer
2023-04-040
PRE
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer

Nivolumab在切除的食管或胃食管交界处癌中的辅助治疗

2021-04-011.0K
OA